



**NEPEAN BLUE MOUNTAINS LOCAL HEALTH DISTRICT HUMAN RESEARCH ETHICS COMMITTEE
CERTIFICATE OF APPROVAL**

Tuesday 14th April 2020

Professor Kazuaki Negishi
Head of Discipline of Medicine
Nepean Clinical School
The University of Sydney
Cardiologist, Nepean Hospital
Kingswood NSW

This letter constitutes ethical approval only. You must **NOT commence this research project at **ANY** site until you have submitted a Site Specific Application to the RESEARCH GOVERNANCE OFFICER and received a separate authorisation from the Chief Executive or their delegate.**

Dear Professor Negishi,

HREC study reference: 2019/ETH13335

Study title: - Restoring microvascular circulation with diagnostic ultrasound and contrast: The REDUCE Trial.

*Your request to undertake the above protocol was considered by the NBMLHD Human Research Ethics Committee (HREC) at its meetings held on the **5/11/2019, 22/11/2019 and 24/3/2020**.*

*On receipt of your response dated **19/11/2019 & 17/3/2020** to the concerns of the Committee dated **13/11/20219 & 28/11/2020**, we are satisfied that your protocol meets the requirements of the National Statement on Ethical Conduct in Human Research (2007) and was **APPROVED on the 14th April 2020, to be conducted as a single-site study.***

It is the Principal Investigator's responsibility to ensure that all researchers associated with this project are aware of the conditions of approval and which documents have been approved.

The Principle Researcher is required to note the following conditions of approval:

- The coordinating investigator will immediately report anything which might warrant review of ethical approval of the project in the specified format, including unforeseen events that might affect continued ethical acceptability of the project.
- The coordinating investigator will immediately report any protocol deviation / violation, together with details of the procedure put in place to ensure the deviation / violation does not recur.

2019-ETH13335 – Cont'd

- The Coordinating Investigator will provide to the HREC in the specified format proposed amendments to the protocol or conduct of the research which may affect the ethical acceptability of the project. Copies of all proposed changes when approved by the HREC must also be provided to the research governance officer.
- The HREC must be notified, giving reasons, if the project is discontinued at a site before the expected date of completion.
 - The Coordinating Chief Investigator must provide an annual report to the HREC and a final report at completion of the study, in the specified format. HREC approval is granted for a period of 5 years and ongoing approval is contingent upon annual report submission. Annual Reports for all studies should be submitted on the anniversary of the approval date of project. They will be processed and presented to the HREC at the next scheduled meeting. Annual / Final reports must be submitted via REGIS <https://regis.health.nsw.gov.au/>
- It should be noted that compliance with the ethical guidelines is entirely the responsibility of the investigators.
- The HREC has the discretion to adopt other appropriate mechanism for monitoring depending on the complexity, design and risk perceived, including:
 - Discussion of relevant aspects of the project with investigators at any time.
 - Random inspection of research sites, data or consent
 - Interview with research participants or other formats of feedback from them.
 - Request and review reports from independent agencies such as Data and Safety Monitoring Board.
- For clinical trials using implantable medical devices, the coordinating investigator will confirm to the HREC that a process has been established for tracking participants with consent for the lifetime of the device and will immediately report any device incidents to the Therapeutic Goods Administration (TGA).
- If your research project is an interventional trial please ensure you register your trial onto one of the clinical trial registries, for example. <http://www.anzctr.org.au/>
- The storage of study data should be as per the GDA 17 Public Health Patient Records, Section 8.0 Research Management. For Clinical Trials data should be stored for 15 years from the date of publication or completion / termination of the study then destroy. For non-clinical trials study data should be stored for 5 years from the date of publication or completion / termination of the study then destroy. <https://www.records.nsw.gov.au/recordkeeping/rules/gdas/gda17>

The NBMLHD HREC has been accredited by the NSW Ministry of Health as a lead HREC to provide the single ethical and scientific review of proposals to conduct research within the NSW public health system. This lead HREC is constituted and operates in accordance with the National Health and Medical Research Council's *National Statement on Ethical Conduct in Human Research* and the *CPMP/ICH Note for Guidance on Good Clinical Practice for the review of multi-site research proposals*.

SPECIAL CONDITIONS:

- **The Committee noted the following;**
 - **GCP Certification for Professor Kazuaki Negishi – Certificate Number 003062066 Valid 18/2/2020 – 18/2/2023.**
 - **GCP Certification for Dr Faraz Khalid Pathan – Certificate Number 003062143 Valid 6/4/2020 – 6/4/2023.**

2019-ETH13335 – Cont'd

- **GCP Certification for Dr Hisham Hallani – Certificate Number 003061322 Valid 9/12/2019 – 9/12/2022**
- **GCP Certification for Dr Tom Ford – Certificate Number 003031465 Valid 1/10/2018 – v1/10/2020.**
- **DEFINITY (perflutien lipid microsphere injection vial) TGA Public Summary Information Sheet. Product Information.**
- **ARTG Number: 124808.**
- **This study to be conducted under the CTN scheme via the TGA by each participating Local Health District in conjunction with the RGO.**

Approved Documents:

Documents reviewed and approved at the meeting were:

Document	Version	Date
HREA	3	28/11/2019
REDUCE Protocol	4	14/4/2020
Sonothrombolysis Trial Data Collection Sheet	1	21/10/2019
Sonothrombolysis Trial Master Coding Sheet	1	21/10/2019
Delegation Log	1	18/11/2019
Master Participant Information Sheet and Consent Form	3	16/3/2020
Withdrawal Form	1	21/10/2019
SAE Form	1	14/4/2020
Master Safety Reporting for Clinical Trials Therapeutic Goods Appendix 6	1	14/4/2020

Approved Sites:

- **Nepean Hospital Cardiology Department**

Yours Sincerely,



Clinical Professor Ian Seppelt
Chair, Human Research Ethics Committee
Nepean Blue Mountains LHD

Please quote project number and title in all correspondence